In diabetes, being the first implies great advantages.Being a chronic disease of great prevalence, there is great competition among pharmacists for launching new advances.And the Danish Novo Nordisk seems to have stumbled in this race.
Despite having received the approval of its new product-a combination of insulin Tresiba and the Analogue of LPG-1 Victoza called Xultophy-in the United States the same day as its Sanofi rival, on November 21, the French laboratory has reachedFirst the North American market.
Soliqua, also a combination of insulin and analogue of LPG-1, can already be acquired in the US, while Xultophy will have to wait until May to make their appearance due, as they have commented on Novo Nordisk to the specialized environment Fierce Pharma, training needs forPart of the Sales Force of the Danish laboratory.
Thus, the French manufacturer of pharmaceutical products will enjoy four months to get a good market share, launching its product at $ 127 for each 300 dose injector.Novo Nordisk's medicine will have to battle through the price if you want to get a part of the extensive diabetes and US market.
The Danish laboratory does not seem to correct the direction that has led him to announce, at the end of last year, a worldwide cut in his workforce, with up to a thousand affected workers, with the aim of reducing the costs in 2017 up to 150 millioneuros.
